SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-22-028772
Filing Date
2022-11-08
Accepted
2022-11-08 08:43:49
Documents
66
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q ovid-20220930.htm   iXBRL 10-Q 1572623
2 EX-31.1 ovid-2022q3xexx311.htm EX-31.1 10663
3 EX-31.2 ovid-2022q3xexx312.htm EX-31.2 10700
4 EX-32.1 ovid-2022q3xexx321.htm EX-32.1 5789
10 ovid-20220930_g1.jpg GRAPHIC 115486
  Complete submission text file 0001628280-22-028772.txt   6735232

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ovid-20220930.xsd EX-101.SCH 45780
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ovid-20220930_cal.xml EX-101.CAL 57412
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ovid-20220930_def.xml EX-101.DEF 185047
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ovid-20220930_lab.xml EX-101.LAB 546375
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ovid-20220930_pre.xml EX-101.PRE 337786
60 EXTRACTED XBRL INSTANCE DOCUMENT ovid-20220930_htm.xml XML 996027
Mailing Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036
Business Address 1460 BROADWAY SUITE 15044 NEW YORK NY 10036 212-776-4381
Ovid Therapeutics Inc. (Filer) CIK: 0001636651 (see all company filings)

IRS No.: 465270895 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38085 | Film No.: 221367404
SIC: 2834 Pharmaceutical Preparations